Paper39744441
TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling.
Shin J and 11 others. Int J Biol Sci, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling. Papers, record 39744441. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39744441
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endometrial Neoplasms | Major topic |
| Protein Serine-Threonine Kinases | Major topic |
| NF-kappa B | Major topic |
| Signal Transduction | Major topic |
| Proto-Oncogene Proteins c-akt | Major topic |
| Cell Proliferation | Major topic |
| Female | |
| Humans | |
| Cell Line, Tumor | |
| Animals | |
| Mice | |
| Aminopyridines | |
| Mice, Nude | |
| Cell Movement | |
| Mice, Inbred BALB C |
Source PubMed
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20495575 | TGFbeta signalling: a complex web in cancer progression. | Nat Rev Cancer | 2010 | https://conductscience.org/library/papers/20495575 | PubMed |
| 2 | 25187272 | NF-κB, an active player in human cancers. | Cancer Immunol Res | 2014 | https://conductscience.org/library/papers/25187272 | PubMed |
| 3 | 33310066 | Tank Binding Kinase 1 modulates spindle assembly checkpoint components to regulate mitosis in breast and lung cancer cells. | Biochim Biophys Acta Mol Cell Res | 2021 | https://conductscience.org/library/papers/33310066 | PubMed |
| 4 | 28716898 | TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer. | Cancer Res | 2017 | https://conductscience.org/library/papers/28716898 | PubMed |
| 5 | 32444850 | Visualizing and interpreting cancer genomics data via the Xena platform. | Nat Biotechnol | 2020 | https://conductscience.org/library/papers/32444850 | PubMed |
| 6 | 29532994 | CiRS-7 targeting miR-7 modulates the progression of non-small cell lung cancer in a manner dependent on NF-κB signalling. | J Cell Mol Med | 2018 | https://conductscience.org/library/papers/29532994 | PubMed |
| 7 | 23836654 | Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/23836654 | PubMed |
| 8 | 27287717 | IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR. | Cancer Res | 2016 | https://conductscience.org/library/papers/27287717 | PubMed |
| 9 | 30808672 | AKT as a Therapeutic Target for Cancer. | Cancer Res | 2019 | https://conductscience.org/library/papers/30808672 | PubMed |
| 10 | 30082428 | Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKKε and Reveal Mechanisms for Selective Inhibition. | Mol Pharmacol | 2018 | https://conductscience.org/library/papers/30082428 | PubMed |
| 11 | 32630674 | The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32630674 | PubMed |
| 12 | 28683283 | Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. | Cell Metab | 2017 | https://conductscience.org/library/papers/28683283 | PubMed |
| 13 | 29559975 | TANK-Binding Kinase 1-Dependent Responses in Health and Autoimmunity. | Front Immunol | 2018 | https://conductscience.org/library/papers/29559975 | PubMed |
| 14 | 25581158 | A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis. | Nat Commun | 2015 | https://conductscience.org/library/papers/25581158 | PubMed |
| 15 | 21464307 | IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. | Proc Natl Acad Sci U S A | 2011 | https://conductscience.org/library/papers/21464307 | PubMed |
| 16 | 36988258 | TBK1 promotes thyroid cancer progress by activating the PI3K/Akt/mTOR signaling pathway. | Immun Inflamm Dis | 2023 | https://conductscience.org/library/papers/36988258 | PubMed |
| 17 | 21042276 | Emerging roles for the non-canonical IKKs in cancer. | Oncogene | 2011 | https://conductscience.org/library/papers/21042276 | PubMed |
| 18 | 23082003 | The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/23082003 | PubMed |
| 19 | 34968491 | The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives. | Biochem Pharmacol | 2022 | https://conductscience.org/library/papers/34968491 | PubMed |
| 20 | 24449872 | Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/24449872 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42793128 | Comprehensive Bioinformatic and miRNA-Driven Analysis of the Multimeric Canonical I Kappa B Kinase (IKK) Complex in Uterine Corpus Endometrial Carcinoma (UCEC). | Biomolecules | 2026 | https://conductscience.org/library/papers/42793128 | PubMed |
| 42682354 | Effects of TBK1 genetic polymorphisms and their interactions with hepatitis B virus mutations on the risk of hepatocellular carcinoma in Han Chinese population: a case-control study. | Int J Surg | 2026 | https://conductscience.org/library/papers/42682354 | PubMed |
| 42247008 | Spotlight on cGAS-STING: role in disease pathogenesis and therapeutic potential. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42247008 | PubMed |
| 41488647 | TIR domain proteins: regulatory mechanisms in the tumor immune microenvironment, clinical translation strategies, and prospects for precision therapy applications. | Front Immunol | 2025 | https://conductscience.org/library/papers/41488647 | PubMed |
| 41416429 | Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors (Review). | Int J Oncol | 2026 | https://conductscience.org/library/papers/41416429 | PubMed |
| 41318858 | Repurposing amlexanox as a topical anti-inflammatory and antioxidant intervention for diabetic foot ulcers: insights from in-silico and in-vivo studies. | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/41318858 | PubMed |
| 40468448 | Matrix stiffness-induced IKBKE and MAPK8 signaling drives a phenotypic switch from DCIS to invasive breast cancer. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/40468448 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| IRF3 | 3661 | PubTator's text mining | https://conductscience.org/library/genes/3661 | NCBI Gene |
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| PTK2B | 2185 | PubTator's text mining | https://conductscience.org/library/genes/2185 | NCBI Gene |
| TBK1 | 29110 | PubTator's text mining | https://conductscience.org/library/genes/29110 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39744441
GET https://conductscience.org/api/papers/v1/39744441/references?page=2